Abstract
The response to pazopanib in patients with metastatic renal cell carcinoma (mRCC) has been found to differ in Western and Eastern populations. Here, we analyzed the efficacy and side effects of pazopanib as first-line therapy in 31 consecutive patients with mRCC who were treated at a single Chinese center. Thirty-one consecutive patients with mRCC (20 males and 11 females, median age 59 years) were treated with pazopanib between October 2017 and July 2019. All patients had received a pathological diagnosis of RCC by prior radical nephrectomy or biopsy. All cases were treated with pazopanib (800 mg/day orally) as first-line therapy. Administration was continued until disease progression or unacceptable toxicities occurred. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety were evaluated. Twenty-nine patients were eligible for final analysis. At the median follow-up of 12.7 months, 34.5% (10/29) patients achieved a partial response (PR), 41.4% (12/29) patients had stable disease (SD), seven (24.1%) patients had disease progression (PD), and one patient had died. The ORR and DCR were 34.5% and 75.9%, respectively, and the median PFS was 10.1 months (95% co...Continue Reading
References
Oct 29, 2010·Clinical Medicine Insights. Oncology·Joshua M Lang, Michael R Harrison
Nov 5, 2014·Cancer Metastasis Reviews·J Michael RandallRazelle Kurzrock
Nov 18, 2015·BJU International·Marc R MatranaNizar M Tannir
Feb 3, 2016·Therapeutic Advances in Urology·David Cella, Jennifer L Beaumont
Aug 4, 2016·BMC Urology·Moon Jin KimHo Yeong Lim
Aug 4, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jose Manuel Ruiz-MoralesDaniel Y C Heng
Dec 8, 2016·Frontiers in Pharmacology·Sabrina C CecereCarmine D'Aniello
May 10, 2017·Indian Journal of Cancer·A JoshiK Prabhash
May 19, 2017·Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada·Aly-Khan A LalaniNaveen S Basappa
Apr 15, 2018·Clinical Genitourinary Cancer·Jinhee ParkNicholas J Vogelzang
May 24, 2018·Journal of Hematology & Oncology·Jun GuoRobert Motzer
Aug 8, 2018·Indian Journal of Cancer·A H RudreshaL K Rajeev
Nov 28, 2018·BMC Pharmacology & Toxicology·María José Méndez-VidalEnrique Gallardo
Dec 14, 2018·Journal of Korean Medical Science·Myung Soo KimJinsoo Chung
Jan 5, 2019·BMC Nephrology·So-Yeon JeonChang-Yeol Yim